☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Sotyktu
BMS Reports Results from the P-III (POETYK PSO) Long-Term Extension Study of Sotyktu for Treating Plaque Psoriasis
May 17, 2024
BMS Presents Three Year Results from the P-III (POETYK PSO) LTE Trial of Sotyktu (deucravacitinib) for Moderate-to-Severe Plaque P...
October 12, 2023
Daniel Quirk, SVP, Head of US Medical Affairs at Bristol Meyers Squibb Shares his Views on the US FDA Approval of Sotyktu
April 17, 2023
BMS’ Sotyktu (deucravacitinib) Receives EC’s Approval for the Treatment of Plaque Psoriasis
March 29, 2023
Insights+: EMA Marketing Authorization of New Drugs in January 2023
February 23, 2023
BMS Receives EMA’s CHMP Positive Opinion Recommending Approval of Sotyktu (deucravacitinib) for Plaque Psoriasis
January 27, 2023
Load more...
Back to Home